---
title: 'Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for
  previously treated advanced NSCLC with KRAS G12C mutation'
date: '2024-09-20'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39303400/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240921200343&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Patients receiving sotorasib reported less severe symptoms
  than those receiving docetaxel. In addition to improving clinical efficacy outcomes,
  sotorasib maintained QOL versus docetaxel, suggesting sotorasib may be a more tolerable
  treatment option for patients with pretreated, KRAS G12C-mutated advanced ...'
disable_comments: true
---
CONCLUSIONS: Patients receiving sotorasib reported less severe symptoms than those receiving docetaxel. In addition to improving clinical efficacy outcomes, sotorasib maintained QOL versus docetaxel, suggesting sotorasib may be a more tolerable treatment option for patients with pretreated, KRAS G12C-mutated advanced ...